Login to Your Account



Zalicus finds pain relief via biosimilars in Epirus Pharma all-stock merger pact

By Randy Osborne
Staff Writer

Wednesday, April 16, 2014

Epirus Pharmaceuticals Inc.'s all-stock takeover of Zalicus Inc., disclosed on the same day that Epirus put the wraps on a $36 million series B round, will add early stage pain drug candidates to its pipeline of biosimilars and immediately put some joy back into Zalicus' shares.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription